Pokarna Ltd has agreed to continue Gautam Jain as Chairman and Managing Director, along with Rahul Jain as Managing Director, for a period of five years, starting from May and July 2026 (subject to shareholder approval).

Kush Bohra suggests investing in Aurobindo Pharma, Nava, and Pokarna for quick profits due to their robust technical indicators. He sets targets at Rs 1415/1480 for Aurobindo, Rs 628/645 for Nava, and Rs 945/965 for Pokarna. It's important to monitor these investments closely with stop-loss levels in place.